RxDoctor Payments Data

David Janeway, MD

Family Medicine · Arlington, WANPI 1821177437

Payments from drug & device makers

$3,980in general payments, 2019–2025

Across 197 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$758
  • AbbVie$328
  • Novo Nordisk$318
  • Boehringer Ingelheim$315
  • Lilly USA, LLC$288
  • Johnson & Johnson$174
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$3,95499%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,980 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$72,789
Medicare patients
208
Services billed
987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$182,770
TrulicityDulaglutide102$131,071
OzempicSemaglutide108$127,751
FarxigaDapagliflozin Propanediol140$121,537
JardianceEmpagliflozin114$110,256
XareltoRivaroxaban60$59,829
MounjaroTirzepatide47$56,457
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$38,196
Spiriva RespimatTiotropium Bromide20$21,301
EntrestoSacubitril/Valsartan11$16,125
Fluticasone-SalmeterolFluticasone Propion/Salmeterol92$12,114
Atorvastatin Calcium1,054$11,948
Soliqua 100-33Insulin Glargine/Lixisenatide14$11,466
MyrbetriqMirabegron21$9,743
Varenicline Tartrate17$8,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$288$187,528149 claims
PfizerEliquis$148$182,770194 claims
Boehringer IngelheimJardiance, Spiriva Respimat$315$131,557134 claims
Novo NordiskOzempic$318$127,751108 claims
AstraZenecaFarxiga$758$121,537140 claims
Johnson & JohnsonXarelto$174$59,82960 claims
GSKTrelegy Ellipta$153$38,19643 claims
NovartisEntresto$83$16,12511 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$85$11,46614 claims
Astellas Pharma US IncMyrbetriq$24$9,74321 claims
MerckBelsomra$65$6,05312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Arlington

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →